gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 28 Mar 2014.

Bruton agammaglobulinemia tyrosine kinase

Btk, XLA, Bruton's tyrosine kinase, Xid
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. [provided by RefSeq, Nov 2008] (from NCBI)
Top mentioned proteins: BCR, CAN, Tec, Syk, V1a
Papers using Btk antibodies
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors
von Lindern Marieke et al., In The Journal of Experimental Medicine, 1997
... Rabbit antisera recognizing the mouse EpoR, PLCγ1, Btk, c-Kit, and the antiphosphotyrosine mouse monoclonal antibody PY99 were obtained from Santa Cruz Biotechnology, Inc ...
Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
Nürnberg Bernd et al., In The Journal of Cell Biology, 1997
... and BtkPH, restriction sites were introduced by PCR using the indicated primers, the Advantage™ II PCR enzyme system (CLONTECH Laboratories, Inc.) and the ...
The A and the extended V N-terminal regions of streptococcal protein I/IIf mediate the production of tumour necrosis factor alpha in the monocyte cell line THP-1.
El Khoury Joseph, In PLoS ONE, 1997
... Anti-Btk mouse IgG monoclonal antibodies were from BD Transduction Laboratories (Le Pont de Claix, France) and anti-TNF-α mouse monoclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany) ...
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Nukiwa Toshihiro et al., In Respiratory Research, 1993
... Briefly, mononuclear cells were surface stained with phycoerythrin-labeled anti-CD14 antibody, then fixed, permealized, incubated with anti-BTK monoclonal antibody 48-2H [5] or control IgG1 (Dako, Kyoto, Japan), and then ...
Papers on Btk
Targeting Bruton's tyrosine kinase in B cell malignancies.
Kil et al., Rotterdam, Netherlands. In Nat Rev Cancer, 24 Apr 2014
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.
In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides.
Shotelersuk et al., Bangkok, Thailand. In Arch Immunol Ther Exp (warsz), 23 Apr 2014
UNLABELLED: A novel sequence variant, c.240+109C>A, in the Bruton's tyrosine kinase (BTK) gene was identified in a patient with X-linked agammaglobulinemia.
Ibrutinib inhibits B-cell receptor and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with chronic lymphocytic leukemia.
Wiestner et al., Bethesda, United States. In Blood, 21 Apr 2014
We evaluated the in vivo effects of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor on tumor cell activation and proliferation in blood, lymph node, and bone marrow of patients with CLL.
Update on the Biology and Treatment Options for Hairy Cell Leukemia.
Ravandi et al., Houston, United States. In Curr Treat Options Oncol, 21 Apr 2014
Ongoing and planned clinical trials are assessing various treatment strategies, such as the combination of purine analogues and various anti-CD20 monoclonal antibodies, recombinant immunotoxins targeting CD22 (e.g., moxetumomab pasudotox), BRAF inhibitors, such as vemurafenib, and B-cell receptor signaling inhibitors, such as ibrutinib, which is a Bruton's tyrosine kinase inhibitor.
Impaired B Cell Receptor Signaling Is Responsible for Reduced TACI Expression and Function in X-Linked Immunodeficient Mice.
Akkoyunlu et al., Bethesda, United States. In J Immunol, 19 Apr 2014
UNLABELLED: Immune response to T cell independent type 2 (TI-2) Ags, such as bacterial polysaccharides, is severely impaired in X-linked immunodeficient (XID) mice.
Btk29A promotes Wnt4 signaling in the niche to terminate germ cell proliferation in Drosophila.
Yamamoto et al., Sendai, Japan. In Science, 17 Feb 2014
Btk29A is the Drosophila ortholog of the mammalian Bruton's tyrosine kinase (Btk), mutations of which in humans cause a heritable immunodeficiency disease.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Byrd et al., Houston, United States. In Lancet Oncol, Jan 2014
We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia.
Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose, Omaha, United States. In Am J Hematol, Dec 2013
At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor) or lenalidamide (anti-angiogenesis) are approved agents.
[Chemotherapy-free treatment of chronic lymphocytic leukemia?].
Wendtner, München, Germany. In Dtsch Med Wochenschr, Oct 2013
Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform.
Tyrosine kinases, drugs and Shigella flexneri dissemination.
Agaisse et al., New Haven, United States. In Gut Microbes, Oct 2013
We have recently uncovered that, in intestinal epithelial cells, S. flexneri actin-based motility is regulated by the Bruton's tyrosine kinase (Btk).
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
Rickert, Los Angeles, United States. In Nat Rev Immunol, Aug 2013
Indeed, the encouraging results of several ongoing clinical trials that target the activity of phosphoinositide 3-kinase δ-isoform (PI3Kδ), Bruton tyrosine kinase (BTK) or spleen tyrosine kinase (SYK) downstream of the BCR highlight the therapeutic potential of inhibiting BCR signalling.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
O'Brien et al., Columbus, United States. In N Engl J Med, Aug 2013
Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.
Towards targeted therapy of chronic lymphocytic leukemia.
Wiestner et al., Bethesda, United States. In Adv Exp Med Biol, 2012
In particular, the BTK inhibitor ibrutinib and the PI3K inhibitor idelalisib (GS-1101) are two evolving targeted therapies with the most mature clinical data.
The CLL cell microenvironment.
Burger, Houston, United States. In Adv Exp Med Biol, 2012
This chapter summarizes current knowledge about cellular and molecular interactions between CLL cells and their supportive tissue microenvironment and the therapeutic targets that are emerging, focusing on the CXCR4-CXCL12 axis and small molecule inhibitors that are targeting the B cell receptor-associated kinases SYK, BTK, and PI3Kδ.
Ibrutinib and novel BTK inhibitors in clinical development.
Liu et al., Valhalla, United States. In J Hematol Oncol, 2012
Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.
Tyrosine kinase Btk is required for NK cell activation.
Cao et al., Shanghai, China. In J Biol Chem, 2012
Data suggest a role of tyrosine kinase Btk in the regulation of immune cell unctions and innate inflammatory response.
Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).
Nore et al., Huddinge, Sweden. In Mol Cell Biol, 2012
mapped the interaction site to the C terminus of the Btk SH3 domain
Single-chain variable fragment intrabody impairs LPS-induced inflammatory responses by interfering with the interaction between the WASP N-terminal domain and Btk in macrophages.
Kitani et al., Tsukuba, Japan. In Biochem Biophys Res Commun, 2012
These observations strongly suggest that the phosphorylation of WASP by Btk plays a pivotal role in transducing the LPS signaling pathway in macrophages.
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.
Hendriks et al., Rotterdam, Netherlands. In Blood, 2012
Transgenic mice overexpressing Btk specifically in B cells spontaneously formed germinal centers and manifested increased plasma cell numbers, leading to antinuclear autoantibody production and systemic lupus erythematosus (SLE)-like autoimmune pathology.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Lam et al., Singapore, Singapore. In Proc Natl Acad Sci U S A, 2012
BTK plays a critical role in initiating TLR3 signaling.
share on facebooktweetadd +1mail to friends